Core Points - Opendoor Technologies Inc. announced the distribution of warrants to purchase common stock to registered stockholders and certain convertible noteholders on November 21, 2025, as part of a special dividend [1][2] - Each stockholder of record as of November 18, 2025, received three series of warrants (Series K, Series A, and Series Z) at a ratio of one warrant per thirty shares held [1][3] - The CEO emphasized that this warrant dividend reflects confidence in the company's business and aims to strengthen the relationship with shareholders [2] Warrant Terms - Eligibility for receiving warrants is based on being a shareholder of record as of the Record Date, November 18, 2025 [3] - The distribution ratio is one warrant of each series for every thirty shares held, with no fractional warrants issued [3] - Exercise prices are set at $9.00 for Series K, $13.00 for Series A, and $17.00 for Series Z [3] - The warrants are exercisable for cash, with a potential for net exercise as per the warrant agreement [3] - Each series of warrants will expire on November 20, 2026, unless the Early Expiration Price Condition is met [3] - The Early Expiration Price Condition requires the daily volume-weighted average price of the common stock to meet or exceed specified trigger prices for each series [3] Additional Information - Shareholders are encouraged to review the company's Investor Relations Resource Page for more information [4] - The warrants are expected to trade on Nasdaq under the tickers OPENW (Series K), OPENL (Series A), and OPENZ (Series Z) [7] - Convertible noteholders of the 7.000% Convertible Senior Notes due 2030 received warrants on the same terms as common stockholders [7]

Core Points - Salarius Pharmaceuticals Inc. shares increased by 23.65% in after-hours trading, closing at $1.21, following the announcement of pricing details for its public offering [1] - The stock had previously dropped 51% during regular trading, closing at $0.98 [1] Offering Details - Salarius announced a public offering aimed at raising approximately $7 million in gross proceeds before fees [2] - The offering includes 2.51 million common stock shares and pre-funded warrants for 2.15 million shares, priced at $1.50 per share [2] Warrant Structure and Terms - The exercise price for both Series A and Series B warrants is set at $1.50 [3] - Series B warrants have a one-year exercise window, while Series A warrants can be exercised for five years after issuance [3] - The warrants feature fixed pricing with no variable pricing elements [3] Merger-Contingent Closing - The closing of the offering is contingent upon the completion of Salarius' proposed business combination with Decoy Therapeutics Inc., expected to occur on Wednesday [4] - Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering [4] - Proceeds from the offering will be used to fund research programs, repay Decoy's promissory notes, and cover working capital needs [4] Stock Performance - Year-to-date, Salarius' stock has decreased by 96.25% [5] - The company has a market capitalization of $1.03 million and an average daily trading volume of 318,090 shares [5] - Benzinga Edge Stock Rankings indicate a negative price trend for SLRX across all time frames [5]

Core Points - Opendoor Technologies Inc. announced a special dividend distribution of warrants to common stockholders as of November 18, 2025, aiming to align management's performance with shareholder benefits [1][2][3] Warrant Distribution Details - The warrants will be distributed on or about November 21, 2025, without any action or payment required from stockholders [4] - Each shareholder will receive three series of warrants (Series K, A, and Z) at a ratio of one warrant per thirty shares held, rounded down [5][6] - The exercise prices for the warrants are set at $9.00 for Series K, $13.00 for Series A, and $17.00 for Series Z, with an expiration date of November 20, 2026 [5][12] Trading and Liquidity - The warrants are expected to be listed on Nasdaq under the tickers OPENW, OPENL, and OPENZ, allowing immediate trading or holding for potential upside [6][12] - The structure of the warrants is designed to be non-dilutive at issuance, protecting current shareholders while enabling upside participation [6][12] Alignment with Shareholders - The program is intended to rebuild trust and ensure that if management succeeds, shareholders benefit directly, emphasizing a structural alignment rather than a theoretical one [2][3] - An investor FAQ will be available to address questions regarding the mechanics of the warrant distribution [9]